A Randomised Phase II Clinical Trial using Targeted Radiotherapy delivered by an Yttrium-90 Radio-labelled Anti-CD66 Monoclonal Antibody with high dose melphalan compared to melphalan alone, prior to Autologous Stem Cell Transplantation for Multiple Myeloma
Laufzeit: 01.01.2009 - 31.12.2012